The Gardasil Controversy: Lawsuits Claim HPV Vaccine Causes Cancer It Aims to Prevent
Originally published: 2025-08-16
In the heart of North Carolina, a surge of lawsuits is putting Merck's blockbuster HPV vaccine, Gardasil, under intense scrutiny. Plaintiffs allege that the shot, marketed as a shield against cervical and other cancers, has instead triggered severe health issues, including the very diseases it was designed to ward off. As appeals drag on and public debate rages, this story highlights the tense intersection of pharmaceutical innovation, patient safety, and legal accountability.
The Spark: A Viral News Segment and Mounting Claims
A recent segment on Queen City News, a Charlotte-based outlet, thrust these lawsuits into the spotlight. Reporter Julian Sadur interviewed chief legal analyst Khalif Rhodes, who dissected the cases with a mix of optimism for plaintiffs and caution about the road ahead. The discussion centered on 185 plaintiffs filing in the U.S. District Court for the Western District of North Carolina, many claiming Gardasil caused autoimmune disorders, neurological problems, and even HPV-related cancers post-vaccination.
These aren't isolated gripes. Consolidated into multidistrict litigation (MDL) under Judge Kenneth D. Bell, the cases have grown steadily since 2022. By July 2025, the MDL encompassed over 100 active lawsuits, with plaintiffs arguing Merck rushed the vaccine to market without adequate testing or warnings.
One poignant example: a lawsuit claiming a young woman died from terminal cervical cancer allegedly linked to the vaccine.
"But not only is it not preventing me from getting cancer, it's also causing cancer."
— Khalif Rhodes, Chief Legal Analyst, Queen City News
Legal Hurdles: Proving Causation in a High-Stakes Battle
Rhodes, a criminal defense attorney, broke down the core elements of these product liability claims: duty, breach, causation, and damages. He suggested causation could be "pretty easy" to argue using the "but for" test, if not for taking Gardasil, the injuries wouldn't have occurred. However, he acknowledged the need for expensive expert witnesses and the challenge of Gardasil being the only HPV vaccine available, potentially weakening claims of alternatives.
Despite Rhodes' view that these cases have "money written all over it," courts have sided with Merck so far. In March 2025, Judge Bell granted summary judgment in over 200 cases, ruling federal law preempts state failure-to-warn claims due to insufficient evidence linking Gardasil to side effects like Postural Orthostatic Tachycardia Syndrome (POTS) or premature ovarian failure.
Plaintiffs appealed to the Fourth Circuit Court of Appeals in July 2025, citing a "vast body of evidence" of risks and hoping to revive the suits.
The first jury trial kicked off in January 2025 over marketing safety claims, but outcomes remain unclear amid ongoing appeals.
Rhodes predicted large settlements or punitive damages if juries get involved, but Merck's defenses, bolstered by FDA approval and global studies claimed to show the vaccine's efficacy, pose significant barriers.
"This will be a large payout, a significant settlement if it ever goes to trial, a jury would give extensive punitive damages."
— Khalif Rhodes
Merck's Stance: Defending a Vaccine They Claim is Credited with Saving Lives
Merck vehemently denies the allegations, emphasizing Gardasil's safety record. Approved by the FDA in 2006, the vaccine has been administered to hundreds of millions worldwide and is credited with slashing HPV infections and related cancers.
The company argues no causal link exists between the vaccine and the claimed injuries, pointing to rigorous trials and post-market surveillance. Recent business moves, like pausing Gardasil shipments to China through 2025 due to market weakness, are unrelated to the lawsuits but underscore the vaccine's commercial importance, it's a multi-billion-dollar product for Merck.
RFK Jr.'s Shadow: Politics Meets Litigation
Adding fuel to the fire is Robert F. Kennedy Jr., whose vaccine safety advocacy has intertwined with these cases. Kennedy has referred clients to firms suing Merck, earning over $850,000 in fees from Gardasil litigation in 2024 alone.
He's played a key role in organizing the suits and vows to overhaul the National Vaccine Injury Compensation Program, potentially reviving arguments against Gardasil.
Critics see this as a conflict, while supporters view it as exposing Big Pharma flaws. As of August 2025, Kennedy's plans to target the federal "vaccine court" continue to make headlines, amplifying skepticism around vaccines.
"The research lacked... it should have been a deeper breath of information."
— Khalif Rhodes on alleged rushed development
Looking Ahead: Implications for Public Health and Trust
These lawsuits could expand if appeals succeed, drawing more plaintiffs inspired by media coverage. Yet, health experts warn against alarmism: The CDC and FDA affirm Gardasil's benefits far outweigh risks for most people.
Still, the controversy erodes trust in vaccines, especially amid broader debates fueled by figures like Kennedy. For those affected, consulting a product liability attorney is key. As Rhodes noted, the pool of claimants may grow, but proving causation in court remains an uphill battle. This saga isn't just about one vaccine, it's a litmus test for how society balances supposed innovation with accountability.
